Gynecologic Cancers

Immunotherapy alone has not shown much success in treating ovarian cancer, despite success with other cancers, so researchers are now testing combinations of immunotherapy drugs with other agents to see if it enhances effectiveness.

Cisplatin, a platinum-based chemotherapy agent that is used to treat testicular cancer, non-small cell lung cancer, bladder cancer, cervical cancer, ovarian cancer and head and neck cancer, has been found to cause a significant amount of hearing loss in patients, according to a recent article published in Nature Communications.

Blueberries are known as a "superfood" because of the rich essential vitamins and minerals they provide. Research now shows they may also help to treat cancer.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses the work ahead in the ovarian cancer field.

PARP inhibitor Rucaparib may soon be available to a wider group of patients with ovarian cancer.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

Current diagnostic measures for ovarian cancer are not extremely reliable. In an effort to diagnose the disease earlier, researchers are working on a blood test that can detect ovarian cancer

The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.

A California woman has been awarded $417 million after alleging that Johnson & Johnson’s talcum-based Baby Powder led to ovarian cancer. The jury award may be the largest yet concerning the product.

Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Ovarian cancer expert, David M. Gershenson, MD, from University of Texas MD Anderson Cancer Center discusses three treatments for some of the rare types of ovarian cancers and the challenges to treating these diseases.

Ovarian cancer screening for women who do not have symptoms of the disease may do more harm than good, according to the USPSTF.

The treatment landscape of ovarian cancer continues to change with the recent approvals of new agents.

For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.

Maintenance rucaparib may improves progression-free survival in patients with ovarian cancer.

Clinicals can use mutiple-gene panels to identify mutations to test for breast cancer and ovarian cancer risk.

A recent study has shown that the cancer risks for women with BRCA1 and BRCA2 mutations depend on the extent of the woman’s family history of cancer and the position of the specific fault within the gene.

Expert Ilana Cass, MD, explains the options that women with have when it comes to preventing ovarian cancer.

Communication is key when it comes to discussing genetic information and hereditary cancers with family members.

A recent survey found that women with ovarian cancer are uncertain of what to expect, and experience a gap when communicating with healthcare providers.

More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).

The human papillomavirus (HPV) vaccine has reduced the prevalence of high-risk oral HPV infections by 88& in young adults that have had at least 1 dose of the vaccine.

A recent analysis showed that many women within the recommended age for routine screening are not up to date on Pap tests.

A recent study has found correlations between common comorbidities (hypertension, heart disease, diabetes, etc) and ovarian cancer.

For BRCA1/2 and other genes, it is important that practitioners begin testing for heriditary genes for ovarian cancers.

As prevalence of HPV within the population rises, incidence of HPV-related cancers is expected to rise.

Fewer people are dying from cancer than years ago, according to a recent study.

The FDA has granted approval for the PARP inhibitor niraparib for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial repsponse to platinum-based chemotherapy.

For patients with BRCA+ ovarian cancer, olaparib in the maintenance setting has shown impressive progression free survival benefits.

When we, as navigators, wake up each morning, we never know what we will be asked to accomplish in the care of our patients and their families.